(Q35226258)

7 August 2017

1 reference

title

Treatment options for endometrial cancer: experience with topotecan (English)

1 reference

7 August 2017

1 reference

Robert W Holloway

1

1 reference

7 August 2017

language of work or name

English

0 references

publication date

1 September 2003

1 reference

7 August 2017

1 reference

7 August 2017

volume

90

1 reference

7 August 2017

issue

3 Pt 2

1 reference

7 August 2017

page(s)

S28-33

1 reference

Current status and future innovations of hormonal agents, chemotherapy and investigational agents in endometrial cancer

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900468-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900468-2

1 reference

7 January 2021

Systemic therapy for advanced or recurrent endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900468-2

7 January 2021

Prospective treatment of advanced or recurrent endometrial carcinoma with cisplatin, doxorubicin, and cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900468-2

7 January 2021

A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900468-2

7 January 2021

Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900468-2

7 January 2021

Phase II study of carboplatin in patients with advanced or recurrent endometrial carcinoma. A trial of the EORTC Gynaecological Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900468-2

7 January 2021

Cyclophosphamide or ifosfamide in patients with advanced and/or recurrent endometrial carcinoma: a randomized phase II study of the EORTC Gynecological Cancer Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900468-2

7 January 2021

A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900468-2

7 January 2021

Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900468-2

7 January 2021

Taxol is active in platinum-resistant endometrial adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900468-2

7 January 2021

Phase II study of paclitaxel as salvage treatment in advanced endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900468-2

7 January 2021

Persistent chemosensitivity to platinum and/or paclitaxel in metastatic endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900468-2

7 January 2021

Platinum neurotoxicity: clinical profiles, experimental models and neuroprotective approaches

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900468-2

7 January 2021

Anthracyclines in the treatment of gynecologic malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900468-2

7 January 2021

Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900468-2

7 January 2021

A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: a gynecologic oncology group study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900468-2

7 January 2021

Weekly topotecan in the management of ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900468-2

7 January 2021

Phase ii comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900468-2

7 January 2021

A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900468-2

7 January 2021

Topotecan is an active agent in the first-line treatment of metastatic or recurrent endometrial carcinoma: Eastern Cooperative Oncology Group Study E3E93.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900468-2

7 January 2021

10.1016/S0090-8258(03)00468-2

Identifiers

DOI

1 reference

release_ebldexekxvgo5eectz5zft5s5i

7 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ebldexekxvgo5eectz5zft5s5i

24 November 2022

mapped directly with Wikidata item

1 reference